Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous angiogenic cell precursors
- Development stage
- Phase 2
- Lead developer
- Hemostemix
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramuscular, Intramyocardial, Intra-arterial
01
Overview
Autologous angiogenic cell precursors (ACPs), also known by the development code ACP-01 and the brand name VesCell, are a specialized population of blood-derived stem cells developed by Hemostemix. The therapy is produced by collecting a patient's peripheral blood, from which angiogenic cell precursors are isolated and expanded ex vivo using a proprietary process. These cells are then delivered via local injection (e.g., intramuscularly for critical limb ischemia or intramyocardially for heart disease) to promote the formation of new microvasculature and restore blood flow to ischemic tissues. ACP-01 has reached Phase III clinical development for critical limb-threatening ischemia (CLTI) and is being explored for other cardiovascular conditions and vascular dementia. Hemostemix has established a manufacturing partnership with CytoImmune Therapeutics to utilize automated cell therapy systems for scaled production.
- Brand names
- VesCell
- Other names
- ACPsautologous angiogenic cell precursorsVescell TMblood-derived autologous angiogenic cell precursors
Beyond the preview
Go deeper on autologous angiogenic cell precursors.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous angiogenic cell precursors.